HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Unity Biotechnology (NASDAQ:UBX) and maintained a price target of $8.
August 08, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Unity Biotechnology (NASDAQ:UBX) and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target at $8 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100